From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|December 6, 2016
What Are the Challenges in Managing Pediatric Epilepsy?
Joseph Sullivan, MD—associate professor at the University of California San Francisco, director of USCF Pediatric Epilepsy Center—discusses some of the challenges in managing pediatric epilepsy.
Advertisement
Joseph Sullivan, MD—associate professor at the University of California San Francisco, director of USCF Pediatric Epilepsy Center—discusses some of the challenges in managing pediatric epilepsy.
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
Glucose Monitoring: Timing Makes Every Reading Count
4
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
5